K. Winter

发表

Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Jeffrey Bradley, James A Purdy, J. Bradley, 2005, International journal of radiation oncology, biology, physics.

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

A. Markoe, K. Russell, H. Sandler, 2000, International journal of radiation oncology, biology, physics.

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

A. Markoe, J. Earle, H. Sandler, 2002, International journal of radiation oncology, biology, physics.

Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial

J. Galvin, H. Sandler, J. Bahary, 2013 .

Acute and late toxicity results of RTOG 9311: a dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer

J. Bradley, R. Komaki, J. Purdy, 2003 .

Preliminary results of a radiation therapy oncology group trial (RTOG 9311), a dose escalation study using 3d conformal radiation therapy in patients with inoperable nonsmall cell lung cancer

J. Bradley, R. Komaki, J. Purdy, 2001 .

Fit of a Generalized Lyman Normal-Tissue Complication Probability (NTCP) Model to Grade ≥ 2 Late Rectal Toxicity Data From Patients Treated on Protocol RTOG 94-06

Lei Dong, R. Mohan, D. Kuban, 2007 .

Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406

A. Markoe, H. Sandler, J. Purdy, 2000 .

Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV

A. Markoe, H. Sandler, J. Purdy, 2002 .

Estimation of α/β for late rectal toxicity based on RTOG 94-06.

Lei Dong, R. Mohan, J. Purdy, 2011, International journal of radiation oncology, biology, physics.

Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.

Lei Dong, R. Mohan, D. Kuban, 2010, International journal of radiation oncology, biology, physics.

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O

D. Grignon, H. Sandler, Chin-Lee Wu, 2005, International journal of radiation oncology, biology, physics.

An Overview of Phase II Clinical Trial Designs.

K. Winter, P. Torres-Saavedra, 2021, International journal of radiation oncology, biology, physics.

NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)

L. Dawson, A. Zhu, E. Koay, 2022, International Journal of Radiation Oncology*Biology*Physics.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Jeff M Michalski, Mack Roach, James A Purdy, 2005, International journal of radiation oncology, biology, physics.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Richard K Valicenti, Jeff M Michalski, Mack Roach, 2004, International journal of radiation oncology, biology, physics.

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

J. Galvin, H. Sandler, W. Bosch, 2013, International journal of radiation oncology, biology, physics.

RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma.

R. Abrams, C. Willett, A. Benson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

A. Markoe, H. Sandler, J. Purdy, 2004, International journal of radiation oncology, biology, physics.

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.

A. Markoe, H. Sandler, J. Purdy, 2003, International journal of radiation oncology, biology, physics.

Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.

A. Markoe, H. Sandler, J. Purdy, 2002, Seminars in radiation oncology.

Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.

R. Mohan, J. Purdy, W. Bosch, 2012, International journal of radiation oncology, biology, physics.

NRG RTOG 1005: A Phase III Trial of Hypo Fractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation Plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer

F. Vicini, J. Hayman, J. Tomberlin, 2022, International Journal of Radiation Oncology*Biology*Physics.

Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

D. Brachman, C. Catton, H. Sandler, 2018, International Journal of Radiation Oncology*Biology*Physics.

Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.

J. Purdy, M. Roach, W. Bosch, 2004, International journal of radiation oncology, biology, physics.

RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

H. Sandler, J. Purdy, R. Valicenti, 2003, International journal of radiation oncology, biology, physics.

Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.

R. Mohan, J. Purdy, W. Bosch, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Preliminary Analysis of 3D-CRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Toxicity Report

J. Galvin, H. Sandler, J. Michalski, 2011 .

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

D. Grignon, P. Rubin, W. Sause, 2001, International journal of radiation oncology, biology, physics.

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.

W. Sause, G. Hanks, M. Rotman, 1998, International journal of radiation oncology, biology, physics.

1011 : A Review of the Activities of the ITC in Support of RTOG Advanced Technology Clinical Trials

W. Curran, J. Purdy, W. Bosch, 2006 .

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

G. Hanks, K. Winter, M. Machtay, 2001, International journal of radiation oncology, biology, physics.

Estimation of α/β for late rectal toxicity based on RTOG 94-06.

R. Mohan, J. Purdy, W. Bosch, 2011, International journal of radiation oncology, biology, physics.